Related references
Note: Only part of the references are listed.First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial
Paul Baas et al.
LANCET (2021)
Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma
Zhuting Hu et al.
NATURE MEDICINE (2021)
Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition
Kevin Litchfield et al.
CELL (2021)
Microsatellite instability and immune checkpoint inhibitors: toward precision medicine against gastrointestinal and hepatobiliary cancers
Yuji Eso et al.
JOURNAL OF GASTROENTEROLOGY (2020)
Unraveling Triple-Negative Breast Cancer Tumor Microenvironment Heterogeneity: Towards an Optimized Treatment Approach
Yacine Bareche et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2020)
Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence
Samuel J. Klempner et al.
ONCOLOGIST (2020)
Peptide-Based Vaccines: Current Progress and Future Challenges
Ryan J. Malonis et al.
CHEMICAL REVIEWS (2020)
The future of cancer immunotherapy: microenvironment-targeting combinations
Yonina R. Murciano-Goroff et al.
CELL RESEARCH (2020)
A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancer
Mark Yarchoan et al.
CANCER MEDICINE (2020)
Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy
Chongxian Pan et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
MHC-I genotype and tumor mutational burden predict response to immunotherapy
Aaron M. Goodman et al.
GENOME MEDICINE (2020)
Evaluating the Potential of T Cell Receptor Repertoires in Predicting the Prognosis of Resectable Non-Small Cell Lung Cancers
Zhengbo Song et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2020)
T cell receptor repertoire characteristics both before and following immunotherapy correlate with clinical response in mesothelioma
Heleen Vroman et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence
Raju K. Vaddepally et al.
CANCERS (2020)
Geospatial immune variability illuminates differential evolution of lung adenocarcinoma
Khalid AbdulJabbar et al.
NATURE MEDICINE (2020)
The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) >= 10: a decision centered on empowering patients and their physicians
V. Subbiah et al.
ANNALS OF ONCOLOGY (2020)
The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications
Yuanyuan Zhang et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2020)
A Clinician's Guide to Cancer-Derived Exosomes: Immune Interactions and Therapeutic Implications
Matthew C. Knox et al.
FRONTIERS IN IMMUNOLOGY (2020)
T-cell receptor repertoire analysis for the diagnosis and treatment of solid tumor: A methodology and clinical applications
Na Li et al.
CANCER COMMUNICATIONS (2020)
A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer
Patrick A. Ott et al.
CELL (2020)
Characteristics of TCR Repertoire Associated With Successful Immune Checkpoint Therapy Responses
Joel Kidman et al.
FRONTIERS IN IMMUNOLOGY (2020)
Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors
Rilan Bai et al.
BIOMARKER RESEARCH (2020)
Combined TCR Repertoire Profiles and Blood Cell Phenotypes Predict Melanoma Patient Response to Personalized Neoantigen Therapy plus Anti-PD-1
Asaf Poran et al.
CELL REPORTS MEDICINE (2020)
Cancer neoantigen: Boosting immunotherapy
Peijia Xu et al.
BIOMEDICINE & PHARMACOTHERAPY (2020)
Turning Cold into Hot: Firing up the Tumor Microenvironment
Qianqian Duan et al.
TRENDS IN CANCER (2020)
Predictors for clinical benefit of immune checkpoint inhibitors in advanced non-small-cell lung cancer: a meta-analysis
Hazem El-Osta et al.
IMMUNOTHERAPY (2019)
Neoantigen-directed immune escape in lung cancer evolution
Rachel Rosenthal et al.
NATURE (2019)
Safety of nivolumab in combination with dendritic cell vaccines in recurrent high-grade glioma.
Katherine B. Peters et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Determinants for Neoantigen Identification
Andrea Garcia-Garijo et al.
FRONTIERS IN IMMUNOLOGY (2019)
Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade
Nicolas Jacquelot et al.
CELL RESEARCH (2019)
The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy
Todd C. Knepper et al.
CLINICAL CANCER RESEARCH (2019)
Neoantigen vaccine: an emerging tumor immunotherapy
Miao Peng et al.
MOLECULAR CANCER (2019)
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Cemiplimab-rwlc as first and only treatment for advanced cutaneous squamous cell carcinoma
Saqib R. Ahmed et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2019)
Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials
Jonathan G. Pol et al.
ONCOIMMUNOLOGY (2019)
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
T. A. Chan et al.
ANNALS OF ONCOLOGY (2019)
Cancer Neoantigens
Ton N. Schumacher et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 37, 2019 (2019)
Delivery technologies for cancer immunotherapy
Rachel S. Riley et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
A comprehensive study of immunology repertoires in both preoperative stage and postoperative stage in patients with colorectal cancer
Xicheng Liu et al.
MOLECULAR GENETICS & GENOMIC MEDICINE (2019)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Increased diversity with reduced diversity evenness of tumor infiltrating T-cells for the successful cancer immunotherapy
Akihiro Hosoi et al.
SCIENTIFIC REPORTS (2018)
Cancer vaccine: learning lessons from immune checkpoint inhibitors
ZhenLong Ye et al.
JOURNAL OF CANCER (2018)
Immune-related adverse events with immune checkpoint inhibitors in thoracic malignancies: focusing on non-small cell lung cancer patients
Jordi Remon et al.
JOURNAL OF THORACIC DISEASE (2018)
Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion
Flavia Castro et al.
FRONTIERS IN IMMUNOLOGY (2018)
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
L. Horn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Colorectal cancer vaccines: Tumor-associated antigens vs neoantigens
Sandra Wagner et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2018)
Dendritic Cell Cancer Therapy: Vaccinating the Right Patient at the Right Time
Wouter W. van Willigen et al.
FRONTIERS IN IMMUNOLOGY (2018)
High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors
Saman Maleki Vareki
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Comparison of the Toxicity Profile of PD-1 Versus PD-L1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Analysis of the Literature
Rathi N. Pillai et al.
CANCER (2018)
The Different T-cell Receptor Repertoires in Breast Cancer Tumors, Draining Lymph Nodes, and Adjacent Tissues
Ting Wang et al.
CANCER IMMUNOLOGY RESEARCH (2017)
PD-L1 induced by IFN-γ from tumor-associated macrophages via the JAK/STAT3 and PI3K/AKT signaling pathways promoted progression of lung cancer
Xiaohui Zhang et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2017)
IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade
Mark Ayers et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study
Matthew D. Hellmann et al.
LANCET ONCOLOGY (2017)
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
S. J. Antonia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer
D. P. Carbone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Immunomodulatory Monoclonal Antibodies in Combined Immunotherapy Trials for Cutaneous Melanoma
Mariana Aris et al.
FRONTIERS IN IMMUNOLOGY (2017)
Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy
Jianjun Gao et al.
CELL (2016)
Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation
Ana C. Anderson et al.
IMMUNITY (2016)
Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment
Stefani Spranger
INTERNATIONAL IMMUNOLOGY (2016)
Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy
Weijie Ma et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Global burden of cancers attributable to infections in 2012: a synthetic analysis
Martyn Plummer et al.
LANCET GLOBAL HEALTH (2016)
Classification of Advanced Human Cancers Based on Tumor Immunity in the MicroEnvironment (TIME) for Cancer Immunotherapy
Yu Zhang et al.
JAMA ONCOLOGY (2016)
TCR diversity - a universal cancer immunotherapy biomarker?
Douglas G. McNeel
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
Oncology Meets Immunology: The Cancer-Immunity Cycle
Daniel S. Chen et al.
IMMUNITY (2013)
Molecular Pathways: Next-Generation Immunotherapy-Inhibiting Programmed Death-Ligand 1 and Programmed Death-1
Daniel S. Chen et al.
CLINICAL CANCER RESEARCH (2012)
Combining immunotherapy and targeted therapies in cancer treatment
Matthew Vanneman et al.
NATURE REVIEWS CANCER (2012)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Cancer Immunotherapy Comes of Age
Suzanne L. Topalian et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
The cancer vaccine roller coaster
Bruce Goldman et al.
NATURE BIOTECHNOLOGY (2009)
Antigen-specific immunotherapy and cancer vaccines
E Jäger et al.
INTERNATIONAL JOURNAL OF CANCER (2003)
Epitope spreading in immunemediated diseases: Implications for immunotherapy
CL Vanderlugt et al.
NATURE REVIEWS IMMUNOLOGY (2002)
Clinical trial designs for the early clinical development of therapeutic cancer vaccines
RM Simon et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Share Paper
